I think I can get two, maybe three, papers out of this:
I think I can get two, maybe three, papers out of this:
- Estimate the joint probability of success and Plan Normalized duration.
- Estimate the joint probability of success and Plan Normalized duration.
- Estimate a model similar to EK's model of market vs scientific failure.
- Estimate a model similar to EK's model of market vs scientific failure, incorporating the previous point.
- Develop a structural model that includes a policy parameter relevant to a policy the CBO cares about (Not a high priority yet).
- Develop a structural model that includes a policy parameter relevant to a policy the CBO cares about (Not a high priority yet).
## Questions:
## Questions:
@ -11,6 +11,18 @@ I think I can get two, maybe three, papers out of this:
- What is the effect of `policy` on phase completion and phase transition?
- What is the effect of `policy` on phase completion and phase transition?
- What is the impact of surragate endpoints on phase transition completion? on phase transition?
- What is the impact of surragate endpoints on phase transition completion? on phase transition?
## Value Proposition:
Attempt to build a "cannonical" probabalistic model of the clinical trials process, which will allow for a simple way to test hypotheses regarding the impact of policies and practices on drug development.
### Desired Attributes
- straightforward to re-estimate model and add extensions.
- [Data Processing](https://gitea.kgjk.icu/Research/ClinicalTrialsDataProcessing) is separate and mostly automated.
- An input data standard exists.
- Inference method is well supported.
- Documentation of code exists, and is useful.
# Models
# Models
The general benefit I can provide is to:
The general benefit I can provide is to:
@ -51,10 +63,12 @@ The probabalistic model could then be used to answer various questions, includin
It would also be straightforward to develop simulations from this approach, as the probabilities are right there.
It would also be straightforward to develop simulations from this approach, as the probabilities are right there.
# Estimation Strategy
# Estimation Strategy
Probably use a non-parametric bayesian approach to estimating the probability densities.
Probably use a non-parametric (np-bayesian?) approach to estimating the probability densities.
[[AbrantesMetz-Adams-and-Metz]] use a mixed state proportional hazards model.
## Phase Completion Probabilities:
## Phase Completion Probabilities:
[[AbrantesMetz-Adams-and-Metz]] use a mixed state proportional hazards model.
The goal is to estimate
The goal is to estimate
@ -70,6 +84,8 @@ I may also include the combined phases
I think there might be a way of condensing these using "phase endpoints" as a marker, and not the phase type itself.
I think there might be a way of condensing these using "phase endpoints" as a marker, and not the phase type itself.